摘要
目的分析溶质载体家族7成员11(SLC7A11)在肾透明细胞癌(ccRCC)发生、发展中的作用及其预后价值。方法采用两样本孟德尔随机化分析以识别与ccRCC风险存在因果关系的基因。使用来自UCSC Xena泛癌队列的RNA测序数据及临床数据分析SLC7A11的表达及预后意义。使用TCGA-KIRC数据(训练集)进行基因集富集分析(GSEA)。随后通过逐步Cox回归分析建立了基于SLC7A11的预后模型,并在E-MATB-1980队列(验证集)中进行了外部验证。结果孟德尔随机化分析显示,SLC7A11水平升高会加重ccRCC的患病风险(HR=1.27,95%CI:1.15~1.40,P<0.001)。SLC7A11在各种肿瘤中过表达,并与高T分期和较差的生存预后相关(P<0.05)。GSEA显示SLC7A11富集在增殖和转移相关通路,包括E2F和上皮-间质转化信号通路。SLC7A11预后模型在训练集(1、3、5年AUC=0.78、0.73、0.71)和验证集(1、3、5年AUC=0.70、0.71、0.72)中均显示出强大的预测性能。结论SLC7A11作为ccRCC的潜在生物标志物和治疗靶点,为精准医学提供了新视角。
Objective To investigate the role of solute carrier family 7 member 11(SLC7A11)in the pathogenesis and progression of clear cell renal cell carcinoma(ccRCC)and its prognostic significance.Methods Mendelian randomization analysis was employed to identify genes causally associated with the risk of ccRCC.The expression patterns and prognostic relevance of SLC7A11 were assessed using RNA sequencing data and clinical information obtained from the UCSC Xena pan-cancer cohort.Gene set enrichment analysis(GSEA)was conducted using data from The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma(TCGA-KIRC)dataset(training set).A prognostic model based on SLC7A11 was then developed using stepwise Cox regression and validated externally in the E-MTAB-1980 cohort(validation set).Results Elevated level of SLC7A11 was associated with an increased risk of ccRCC(HR=1.27,95%CI:1.15-1.40,P<0.001).SLC7A11 was overexpressed in various tumors and correlated with higher T stage and poorer survival(P<0.05).GSEA demonstrated that SLC7A11 was enriched in pathways related to proliferation and metastasis,including E2F and epithelial-to-mesenchymal transition signaling pathways.Moreover,the SLC7A11 prognostic model exhibited robust predictive performance in both the training set(1-,3-,and 5-year AUC=0.78,0.73,0.71,respectively)and the external validation set(1-,3-,and 5-year AUC=0.70,0.71,0.72,respectively).Conclusion SLC7A11 can be a potential biomarker and therapeutic target for ccRCC,offering novel perspectives for precision medicine.
作者
李子峰
陈博宏
黄昊翔
冯聪
曾津
陈炜
吴大鹏
LI Zifeng;CHEN Bohong;HUANG Haoxiang;FENG Cong;ZENG Jin;CHEN Wei;WU Dapeng(Department of Urology,The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)
出处
《现代泌尿外科杂志》
CAS
2024年第5期459-465,475,共8页
Journal of Modern Urology
关键词
溶质载体家族7成员11
肾透明细胞癌
生信分析
孟德尔随机化
生物标志物
治疗靶点
solute carrier family 7 member 11(SLC7A11)
clear cell renal cell carcinoma
bioinformation analysis
mendelian randomization
biomarker
therapeutic target
